| Literature DB >> 26887652 |
Nadège Gruel1,2, Laetitia Fuhrmann3, Catalina Lodillinsky4, Vanessa Benhamo5,6, Odette Mariani7, Aurélie Cédenot8, Laurent Arnould9, Gaëtan Macgrogan10, Xavier Sastre-Garau11, Philippe Chavrier12, Olivier Delattre13, Anne Vincent-Salomon14,15.
Abstract
BACKGROUND: Polarity defects are a hallmark of most carcinomas. Cells from invasive micropapillary carcinomas (IMPCs) of the breast are characterized by a striking cell polarity inversion and represent an interesting model for the analysis of polarity abnormalities.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26887652 PMCID: PMC4756502 DOI: 10.1186/s13058-016-0680-x
Source DB: PubMed Journal: Breast Cancer Res ISSN: 1465-5411 Impact factor: 6.466
Fig. 1Polarity abnormalities in invasive micropapillary carcinoma (IMPC). a Representative views of cell-division control protein 42 (CDC42), cis-Golgi marker (GM130) and occludin (OCLN) immunostainings in three normal ducts (left panel) and in three IMPC (right panel). Scale bars 10 μm, L lumen. G × 400 magnification. b Analysis of polarity protein expression and subcellular localization in 24 IMPC. Expression and cellular localization (sub-apical, apical, cytoplasmic, membranous, cell/cell: lateral membrane staining between two cells and basolateral) of polarity proteins was compared to that in normal cells. p-ERM phospho-ezrin-radixin-moesin, p-aPKCζ phospho-atypical PKC, PALS1 protein associated with Lin seven 1, SCRIB Scribble, ZO-1 zonula occludens 1
Fig. 2Specific invasive micropapillary carcinoma (IMPC) gene expression signature. a, b Human Genome U133 set (HG-U133 Plus 2.0) were simultaneously normalized using the GC Robust Multi-array Average package version 2.22.0 to assess the levels of expression of the gene probe sets. Unsupervised hierarchical clustering was performed with the differentially expressed 1108 genes in the training set (a) composed of 63 tumors (37 IMPC and 26 invasive carcinomas of no special type (ICNST)) and in the validation set (b) (61 tumors: 36 IMPC and 25 ICNST). Each column represents a different tumor and each row represents one of 1108 genes. Red bars IMPC, white bars ICNST. c LIN7A gene expression levels according to Affymetrix U133 Plus 2.0 signal in ICNST (n = 51), IMPC (n = 73) and normal breast tissues obtained from mammoplasties (n = 17). P values are based on the Welch two-sample t test; ***p value ≤0.001. d RT-qPCR on LIN7A expression in ICNST (n = 12, black triangles), IMPC (n = 38, white circles) and normal breast samples (n = 10, black diamonds). LIN7A gene expression levels are plotted on the TBP gene expression levels. Median values are indicated (red bars). P values were calculated with the Welch t test and are indicated above the box-plot; **p value ≤0.01. e Western-blot analysis of LIN7A expression in ICNST (n = 8) and IMPC (n = 8) tumors. Blots were incubated with anti-LIN7A or anti-β-actin antibodies as internal control for protein loading
Fig. 3Over-expression of LIN7A disrupts apico-basal polarity, increases proliferation in vitro and enhancestumor growth in vivo. a Phase-contrast images of acinar structures obtained with MCF10A-vector (left) and MCF10A-LIN7A (right) cells (G × 630 magnification). Arrows point to the protrusions from the multi-acinar structures. b Area, perimeter and circularity of MCF10A-vector and MCF10A-LIN7A acini cultured in Matrigel™. Measurements were performed on five independent hematoxylin-and-eosin (HES) stained sections using Adobe Photoshop (Student t test). For circularity, a value of 1.0 indicates a perfect circle. c Quantification of LIN7A-expressing cells invasive potential (MCF10A, left panel; CAMA1, central panel; MDA-MB-231, right panel). ***p-value ≤0.001 (Student t test). d Representative views of KI-67 immunostaining in MCF10A-vector (left panel) and in MCF10A-LIN7A (right panel) acini. Scale bars 20 μm. G × 200 magnification. e Western-blot analysis on MCF10A-vector and MCF10A-LIN7A 3D whole-cell extracts. f Active-caspase-3 stainings of MCF10A-vector (left) and MCF10A-LIN7A (right) acini. Scale bars 20 μm. G × 200 magnification. g Tumor growth in CB17-SCID mice orthotopically injected into the mammary fat pad with MDA-MB-231-vector or MDA-MB-231-LIN7A cells. Curves represent the tumor volume according to time for MDA-MB-231-LIN7A (black squares) and the MDA-MB-231-vector control (white circles); *p value ≤0.05,**p value ≤0.01, ***p-value ≤0.001 (two-way analysis of variance, Bonferroni posthoc test). h Representative pictures of HES stained sections in mice muscle (top panel) or fat-pad (bottom panel) of the MDA-MB-231-vector (left panel) and MDA-MB-231-LIN7A (right panel) tumors, 15 weeks after injection. Scale bars 50 μm. i Representative pictures of KI-67 staining in MDA-MB-231-vector (left panel) and MDA-MB-231-LIN7A (right panel) tumors. Scale bars 50 μm